Monitor Nasdaq listing approval as the closing condition; if approved, the IPO provides ~$26.6M in net proceeds to fund operations and growth initiatives, but the company's minimal revenue base and going-concern risk suggest high execution uncertainty. Watch for any delays in SEC effectiveness or Nasdaq qualification.
Executive Summary
EvoAir Holdings filed Amendment No. 9 to its S-1 registration statement for a firm-commitment IPO of 7,500,000 shares at an estimated $4.00-$5.00 per share, with a 10% over-allotment option. The company, which trades on OTC Pink at $23/share, seeks to uplist to Nasdaq Capital Market. Financials show minimal revenue ($211,613 for 9mo FY2026), persistent net losses ($3.1M same period), and an accumulated deficit of $57M, with a going-concern qualification from auditors. Proceeds of ~$26.6M (net) are earmarked for R&D, expansion, marketing, M&A, shareholder loan repayment, and working capital.
Key Financial Metrics
Key Facts
- Offering: 7,500,000 shares at $4.00-$5.00 per share (firm commitment); 10% over-allotment option for 750,000 additional shares
- Underwriter: Network 1 Financial Securities, Inc.; 7.5% discount, 1% non-accountable expense allowance, and warrants for 5.65% of shares sold
- Revenue: $211,613 for 9 months ended May 31, 2026 (up 32% YoY from $160,359); FY2025 revenue $284,666 (down 10% from $314,719)
- Net loss: $3,121,210 for 9 months ended May 31, 2026 (improved from $7,100,730); FY2025 net loss $14,968,005 (improved from $26,315,396)
- Accumulated deficit: $56,959,317 as of May 31, 2026; cash and cash equivalents only $35,811
- Going concern qualification in audited financial statements; company has not established sustainable revenue to cover operating costs
- Business: Eco-friendly HVAC products (EvoAirTM, e-Cond EVOTM) using proprietary Heat Emission Control System (HECS) technology; also air purifiers and sanitizing products
- Use of proceeds: 15% R&D, 15% expansion capital, 15% advertising, 20% vertical/horizontal integration, 15% repayment of shareholder advances, 20% working capital
- Closing of offering contingent on Nasdaq Capital Market listing approval; no assurance of approval
- Concentration risk: heavy reliance on largest supplier for nano-copper solution (47% of purchases in FY2025)
Financial Impact
IPO gross proceeds of $30M (assuming $4.00/share, no over-allotment); net proceeds ~$26.6M after underwriting discounts and expenses. Net tangible book value per share would increase from $0.03 to $1.01 post-offering, but new investors face 74.76% dilution.
Risk Factors
- Going concern risk with minimal cash ($35,811) and accumulated deficit of $57M
- Nasdaq listing not guaranteed; failure would likely prevent IPO closing
- Extremely low revenue base ($211K in 9 months) with no path to near-term profitability
- High reliance on founder/CEO Dr. Low and single supplier for key nano-copper solution
- Significant dilution to existing shareholders (new investors own 21.6% post-IPO at $4.00/share)
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| S-1/A Filing (EVOH) — Batch item 1 | 0001493152-26-034502 |
| Exhibit: ex1-1.htm | 0001493152-26-034502 |
| Exhibit: ex10-10.htm | 0001493152-26-034502 |
| S-1/A Filing (EVOH) — Batch item 4 | 0001493152-26-034502 |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers